U.S. FDA issues seven observations to Natco Pharma’s Chennai plant

U.S. FDA issues seven observations to Natco Pharma’s Chennai plant

Natco Pharma's active pharmaceutical ingredients unit in Chennai has received seven observations from the U.S. Food and Drug Administration.

The U.S. FDA had conducted an inspection at the API manufacturing plant in Manali, Chennai, from November 17-21. On conclusion, of the inspection, the company received seven observations in the Form-483, the generic drugmaker said on Friday (November 21, 2025).

The company believes the observations are procedural in nature and is confident to address them comprehensively, Natco Pharma said, reaffirming commitment to being cGMP compliant and supplying high-quality products.

Published - November 22, 2025 11:47 am IST

company information

Source: TheHindu
Related Posts: These are the ingredients India's chefs can't wait to cook with in 2026 Gujarat govt orders probe to check presence of harmful ingredients in cough syrups 8 Essential Anti-Aging Ingredients You Should Begin Using In Your 20s Stay Energised This Navratri With These Nutrient-Rich Vrat-Friendly Ingredients Skin lightening creams being sold illegally have dangerous ingredients Two Ingredients The Hidden Risks Of Lipstick Ingredients And Their Link To Lung Cancer Made With Fresh Ingredients To Becoming Part Of The Culture Everyday Ingredients That Can Boost Energy MP has all right ingredients to become IT hub